Worldwide, colorectal cancer (CRC) is the third most common cancer in men and the second most common in women with over half of cases occurring in developed nations ([@bib5]). In the United Kingdom 5-year survival for patients diagnosed with CRC is ∼60% ([@bib6]). Several population-based studies and data from clinical trials have reported that primary tumour location provides prognostic value in terms of patient survival. Over the last few decades most epidemiological studies from western populations report a continued rightward shift of CRC ([@bib1]; [@bib9]; [@bib10]). Cancers of the right colon are more likely to be diagnosed in patients who are older and female; they are associated with locally advanced tumours, with greater mucinous component, poor differentiation-deficient mismatch repair (MMR) and BRAF V600E mutation ([@bib1]; [@bib10]; [@bib8]; [@bib37]; [@bib12]).

The clinical and biological distinction between colon and rectal cancer is widely recognised. Although several studies report that right- and left-sided colonic tumours should be considered as a distinct biological entity, the debate about the clinical relevance of this is ongoing. Moreover, the clinical utility of this distinction remains unclear with little evidence of its relevance to patients with stage I--III potentially curable colon cancer in terms of diagnosis, treatment and follow-up. The benefit of fluorouracil-based adjuvant therapy in CRC is widely recognised; however, in metastatic disease it would appear that right-sided colonic tumours are less responsive to such chemotherapy ([@bib32]). Therefore, a plausible hypothesis is that the prognostic value of tumour location in patients with operable colorectal cancer is dependent on other unmeasured confounding factors. There is a substantial body of evidence that recognises systemic inflammation ([@bib15]; [@bib36]) and the tumour microenvironment as important determinants of disease progression and outcome in both colon and rectal cancer. Inflammation-based prognostic scores that evaluate the systemic inflammatory response (SIR; [@bib15]; [@bib21]) and the tumour microenvironment ([@bib14]; [@bib27]) have yielded prognostic value independent of the widely used TNM staging system and so are candidates as potential confounding factors. The aim of the present study was to examine the relationship between tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing potentially curative surgery for stage I--III colon and rectal cancer.

Materials and methods
=====================

Clinicopathological characteristics
-----------------------------------

Patients were identified from a prospectively collated database of patients undergoing surgery for CRC in a single surgical unit at the Glasgow Royal Infirmary between 1997 and 2016. Patient exclusions were based on the following criteria: metastatic disease including those patients with peritoneal involvement, emergency surgery, surgery with palliative intent, surgery for inflammatory bowel disease-related malignancy, neoadjuvant chemoradiotherapy (excluded due to the potential immunological impact on the tumour microenvironment), familial cancer syndrome, underlying inflammatory condition or mortality within 30 days of surgery. Patients with tumours proximal to the splenic flexure were considered as right-sided. Tumours were staged according to conventional TNM classification with additional data retrieved from pathological reports issued after resection. Routine pathological elastica staining was used to assess the presence of venous invasion ([@bib25]). Following surgery patients were discussed at a local multidisciplinary meeting. Those patients undergoing colonic or rectal surgery with stage III or high-risk stage II disease without significant comorbidity were offered 5-fluorouracil-based adjuvant chemotherapy with or without oxaliplatin, based on the guidelines at the time.

Patients were routinely followed up for 5 years after surgery. Date and cause of death were crosschecked with the cancer registration system and the Registrar General (Scotland). Death records were complete until 1 May 2016; this acted as the censor date for survival analysis. Cancer-specific survival (CSS) was measured from the date of surgery until the date of death from recurrent or metastatic CRC. Overall survival (OS) was measured from date of surgery until date of death from any cause.

Assessment of MMR and BRAF status
---------------------------------

A subset of the patients in the full cohort underwent evaluation of the MMR status, BRAF status and assessment of the tumour microenvironment. Using immunohistochemistry, a previously constructed tissue microarray comprising cores of formalin-fixed paraffin-embedded cancer tissue was used to assess MMR and BRAF status. Immunohistochemistry for MMR status was previously described ([@bib21]). MMR protein expression was reported as MMR-competent or -deficient by a single blinded observer.

For assessment of BRAF status tissue microarrays were dewaxed in xylene and rehydrated with graded alcohols. Antigen retrieval was performed using Tris-EDTA buffer at pH 9 under pressure for 5 min. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 10 min. Casein (10%) was applied for 20 min as a blocking solution. Tissue microarrays were incubated overnight at 4 ^o^C with antihuman BRAF V600E mouse monoclonal antibody (clone VE1, Spring Biosciences, USA) at a concentration of 1 : 200. After washing in TBS, Envision (Dako) was applied for 30 min at room temperature before washing in TBS again. DAB substrate was added for 5 min until colour developed before washing in running water for 10 min. Slides were then counterstained in haematoxylin for 60 s and blued with Scotts' tap water before being dehydrated through a series of graded alcohols. Coverslips were applied using distrene, plasticizer, xylene (DPX). BRAF V600E mutation was reported as absent or present by a single blinded observer.

Assessment of the tumour microenvironment
-----------------------------------------

Assessment of the tumour microenvironment was performed using routine haematoxylin and eosin-stained tissue sections. Klintrup--Mäkinen (KM) score (low/high) and extent of tumour stroma was assessed using tumour stroma percentage (⩽50% low or ⩾50% high), both previously described ([@bib14]; [@bib19]). Tissue sections were also used to assess lymphocytic tumour infiltrate. Immunohistochemistry for CD3^+^ (mature) and CD8^+^ (cytotoxic) T-lymphocytes was performed as per the methodology previously described ([@bib24]). T-lymphocyte density at the invasive margin and within the cancer cell nests was semiquantitatively graded as low or high. Investigators were blinded to clinical data, pathological data and survival outcome.

All cases were co-scored by a second investigator to ensure consistency of scoring.

Assessment of the SIR
---------------------

Serum CRP, albumin and differential white cell count were measured within 30 days before surgery and recorded prospectively. Preoperative SIRs were defined using the modified Glasgow Prognostic Score (mGPS), the neutrophil:lymphocyte ratio (NLR), the neutrophil:platelet score (NPS) and lymphocyte:monocyte ratio (LMR). The mGPS was constructed as described previously ([@bib17]; patients with CRP⩽10 mg/l scored 0, CRP\>10 mg/l scored 1 and CRP\>10 mg/ and albumin\<35 g/L scored 2). On the basis of previously published thresholds, NLR\>5 was considered elevated ([@bib13]). The NPS was calculated as previously described ([@bib35]), platelet count\<400 × 10^9^/l and neutrophil count \<7.5 × 10^9^/l scored 0, either a neutrophil count\>7.5 × 10^9^/l or platelet count\>400 × 10^9^/l scored 1, and those with elevated neutrophils and platelets scored 2. LMR was considered as either low (⩽2.38) or high (\>2.38) as previously described ([@bib7]).

The patient characteristic data in the present study were collected as part of a prospective clinical audit of patients undergoing surgery for CRC in Glasgow Royal Infirmary. Tissue assessment of MMR and BRAF status and the tumour microenvironment was carried out with informed consent. Approval for the audit and for the tissue analysis was given by The West of Scotland Research Ethics Committee.

Statistical analysis
--------------------

The association between tumour location and clinicopathological characteristics, measures of the tumour microenvironment and measures of systemic inflammation were analysed using the *χ*^2^-test. Five-year cancer-specific and OS was examined using Kaplan--Meier log-rank survival analysis and univariate Cox-proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals. Variables found to be statistically significant (*P*\<0.05) on univariate analysis were entered into a Cox regression multivariate model using a backward conditional method. A *P-*value of \<0.05 was considered to be significant. Analyses were performed using SPSS software version 21 (IBM SPSS).

Results
=======

Full cohort
-----------

Overall, 972 patients who underwent elective surgery with curative intent for stage I--III CRC between January 1997 and 2016 were included in the analysis. Clinical and pathological features are shown in [Table 1](#tbl1){ref-type="table"}. Two-thirds of the patients included were over the age of 65 and 55% were male. In all, 178 (18%) patients had TNM stage I disease, 437 (45%) had stage II disease and 356 (37%) patients had stage III disease. Eighty-one patients (16%) with stage II disease and 196 (45%) patients with stage III disease received adjuvant chemotherapy. In the first decade, 24 (12%) patients with stage II and 64 (37%) patients with stage III disease underwent adjuvant chemotherapy. In the latter decade, this increased to 57 (18%) patients with stage II and 132 (51%) patients with stage III disease. Overall, 389 (40%) patients had tumours located within the right colon, 285 (29%) within the left colon and 298 (31%) had rectal cancer.

In terms of clinicopathological characteristics, right-sided tumour location was associated with older age (*P*=0.001), higher T stage (*P*\<0.001), high venous invasion (*P*=0.021), poor tumour differentiation (*P*\<0.001) and MMR deficiency (*P*=0.005) but was not associated with ASA (American Society of Anesthesiology) grade (*P*=0.088), nodal stage (*P*=0.320), marginal involvement (*P*=0.466), tumour necrosis (*P*=0.422) or BRAF status (*P*=0.566). Tumour location was not associated with the administration of adjuvant chemotherapy (*P*=0.632).

When the tumour microenvironment was considered, there was no association between tumour location and Klintrup--Mäkinen Grade (*P*=0.431) or tumour stroma percentage (*P*=0.543). Right-sided tumour location was associated with high CD3^+^ within cancer cell nests (*P*=0.048) but not at the margin (*P*=0.160). Right-sided tumour location was not associated with CD8^+^ within cancer cell nests (*P*=0.666) or at the tumour margin (*P*=0.194).

When the preoperative SIR was considered, right-sided tumour location was associated with a greater SIR as measured by the mGPS (*P*\<0.001) and NPS (*P*\<0.001). Right-sided tumour location was associated with a low preoperative LMR (*P*=0.005; [Table 1](#tbl1){ref-type="table"}).

The relationship between right-sided tumour location and the SIR was examined separately in T1/2, T3 and T4 tumours in the whole cohort. In those patients with T1/2 tumours, right-sided tumour location was not associated with mGPS (*P*=0.404), NLR (*P*=0.393), NPS (*P*=0.247) or LMR (*P*=0.137). In those patients with T3 tumours, right-sided tumour location was directly associated with NPS (*P*=0.001) but was not associated with mGPS (*P*=0.119), NLR (*P*=0.514) or LMR (*P*=0.299). In those patients with T4 tumours, right-sided tumour location was directly associated with mGPS (*P*=0.025), NPS (*P*=0.020) and inversely with LMR (*P*=0.015).

The median follow-up of survivors at time of censor was 54 months (interquartile range: 28--107 months), with 192 cancer-related deaths and 188 non-cancer-related deaths. Right-sided tumour location was not associated with CSS (*P*=0.377) or OS (*P*=0.205; [Table 1](#tbl1){ref-type="table"}).

Univariate analysis in colon cancer patients
--------------------------------------------

On univariate analysis in patients with colonic cancer, age (*P*=0.001), ASA grade (*P*\<0.001), T stage (*P*\<0.001), N stage (*P*\<0.001), venous invasion (*P*=0.002), CD3^+^ within nests (*P*\<0.001), mGPS (*P*\<0.001), NLR (*P*=0.007) and NPS (*P*\<0.001) were associated with reduced CSS. Sex, MMR status, tumour differentiation, LMR and tumour location (that is, left or right colon) were not associated with CSS on univariate analysis. On multivariate analysis, ASA grade (HR 1.91, *P*=0.035), N stage (HR 2.96, *P*\<0.001) and NPS (HR 2.35, *P*=0.005) were independently associated with reduced CSS. Overall, 164 (24%) patients with colon cancer underwent adjuvant chemotherapy. On univariate analysis in this group, T stage (*P*=0.006), mGPS (*P*=0.002) and NPS (*P*=0.010) were associated with reduced CSS. Age, ASA grade, N stage, tumour differentiation, venous invasion, CD3^+^ within cancer nests, NLR, LMR and tumour location were not associated with CSS on univariate analysis. On multivariate analysis mGPS (HR 1.77, *P*=0.050) was independently associated with reduced CSS in patients with colon cancer who had undergone adjuvant chemotherapy.

Adjuvant chemotherapy group
---------------------------

There were 275 patients in the adjuvant group who had undergone elective surgery followed by adjuvant chemotherapy with data available regarding tumour subsite. Overall, 96 (35%) of those patients had primary tumours located within the right colon, 68 (25%) within the left colon and 111 (40%) within the rectum. Clinicopathological characteristics are shown in [Table 2](#tbl2){ref-type="table"}. In terms of patient characteristics, tumour location was not associated with age (*P*=0.583), sex (*P*=0.139) or ASA grade (*P*=0.711). Right-sided tumour location was associated with higher T stage (*P*\<0.001), poor tumour differentiation (*P*=0.058) and high venous invasion (*P*=0.036) but not with nodal stage (*P*=0.398), margin involvement (*P*=0.423), tumour necrosis (*P*=0.779), MMR status (*P*=0.509) or BRAF status (*P*=0.460).

When the tumour microenvironment was considered, tumour location was not associated with the Klintrup--Mäkinen Grade (*p*=0.285) or tumour stroma percentage (*P*=0.875). Right-sided tumour location was associated with high CD3^+^ at the margin (*P*=0.033) and within cancer cells nests (*P*=0.012) but was not associated with CD8^+^ density at the margin (*P*=0.586) or within cancer cell nests (*P*=0.522).

There was no association between tumour location and the SIR as measured by mGPS (*P*=0.597), NLR (*P*=0.183), NPS (*P*=0.066) or LMR (*P*=0.128).

The median follow-up of survivors at time of censor was 56 months (interquartile range: 32--101), with 60 cancer-related deaths and 27 non-cancer-related deaths. There was no significant difference in terms of CSS (*P*=0.302) or OS (*P*=0.076) in the adjuvant group ([Table 2](#tbl2){ref-type="table"}).

Discussion
==========

The results of the present study show that, although right-sided tumour location was associated with factors pertaining to the host, tumour phenotype and features of the tumour microenvironment, it was not prognostic in terms of survival for patients undergoing surgery for stage I--III colon cancer or indeed for those patients within the adjuvant setting. Therefore, the importance of tumour location as a stratification factor in patients with CRC may be secondary to such tumour and host factors.

In the present study, right-sided tumour location was associated with advancing age. Also, consistent with previous studies, right-sided tumour location was associated with a greater proportion of T4 tumours, poor tumour differentiation and presence of venous invasion ([@bib20]; [@bib37]; [@bib4], [@bib3]). For example, [@bib2] reported that, in 17 641 patients over a 3-year period, right-sided colon cancer was more frequently diagnosed in women, older individuals, those with higher ASA grade, locally advanced and lymph node-positive disease.

In the present study, 25% of right-sided tumours were MMR-deficient compared with 11 and 8% of those tumours located within the left colon and rectum, confirming the findings of other studies that report the association of MMR deficiency with right-sided tumour location ([@bib33]). Surprisingly, MMR status was not associated with survival in the full cohort or the adjuvant setting. However, MMR status was only available in a subset of patients (*n*=228). Previous studies have reported the survival benefit conferred by MMR deficiency in the adjuvant setting ([@bib33]; [@bib31]; [@bib29]). For example, the study by [@bib28]) 2580 patients in the adjuvant setting reported that the prognostic impact of MMR deficiency depended on tumour site, where deficient MMR cancers in the right colon had favourable outcomes compared with those in the left colon. Therefore, the lack of prognostic value of MMR in the present study is likely due to the small number of patients examined.

In CRC, the local tumour inflammatory response has been reported as having prognostic value independent of tumour stage ([@bib11]; [@bib26]). The relationship between MMR status, systemic inflammation and tumour lymphocytic infiltrate has been examined previously in this cohort. This previous study showed that MMR was associated with the local immune tumour infiltrate and the SIR; however, MMR had relatively poor prognostic value in comparison to these factors ([@bib21]). Our results suggest a significant association between right-sided tumour location and high density of activated T lymphocytes in the whole cohort and in the adjuvant therapy group. This observation may be explained in part by the association of defective MMR with proximal tumour location and in turn with a coordinated, adaptive intratumoural immune response ([@bib21]). Nevertheless, the present study is the first to examine the relationship between tumour location and the tumour microenvironment.

The results of the present study showed that for the first time right-sided tumour location was consistently associated with an elevated SIR as measured by mGPS, NPS and LMR. The basis of this observation is not clear. However, in the present study right-sided tumour location was associated with higher T stage and previous reports suggest that higher T stage is associated with an increasing SIR; hence, T stage may be a potential confounder. Therefore, in the present study, the relationship between right-sided tumour location and the SIR was examined separately in T1/2, T3 and T4 tumours in the whole cohort. In those patients with T1/2 tumours right-sided tumour location was not associated with the SIR. In contrast, in those patients with T3 and T4 tumours, right-sided tumour location was associated with the SIR (mGPS, NPS and LMR). As the number of patients with T3/T4 tumours was greater in those patients with right-sided tumours, it may be that more tumour invasiveness accounted for the association between right-sided tumour location and the SIR and outcome.

In the present study, there was no association between tumour location and CSS or OS in the full cohort or within the adjuvant group. On univariate analysis in patients with colon cancer, tumour location (that is, right or left) was not associated with CSS or OS or indeed in those patients with colon cancer who had undergone adjuvant chemotherapy. Moreover, results of the present study show that measures of systemic inflammation in patients with colon cancer in the adjuvant and non-adjuvant setting were independently prognostic for CSS. Population-based studies ([@bib18]; [@bib2]), and outcomes of retrospectively analysed oncological trials of patients with metastatic CRC ([@bib16]; [@bib32]) have reported an increase in mortality for right-sided cancers; however, results are conflicting ([@bib37]; [@bib34]). Moreover, they did not adjust for confounders such as the SIR. Therefore, it is of interest that [@bib23] reported that, in more than 22000 patients from 28 randomised clinical trials of patients with metastatic CRC, an elevated SIR as evidenced by an absolute neutrophil count and the derived NLR was associated with early mortality, whereas KRAS status, patient sex, individual sites of metastases, location of primary tumour (colon *vs* rectum), and prior chemotherapy use did not appear to have a prognostic role. In addition, a study evaluating the prognostic role of tumour location in stage III colon cancer patients (PETACC-8 trial) in the context of molecular markers reported that right-sided tumour location was not associated with disease-free survival but was associated with shorter survival after relapse when disease became metastatic and with OS in both MSI-stable and unstable patients ([@bib30]). However, potential confounding factors such as the SIR was not taken into account.

A potential limitation of the present study was that only 45% of patients with stage III CRC received adjuvant therapy. It is well recognised that Glasgow Royal Infirmary serves an area of multiple deprivation. As a consequence, many patients have multiple comorbidities and this precludes the use of chemotherapy. Moreover, as the present study spans a period between 1997 and 2016, a period effect should be appreciated. In the present study this effect was demonstrated by the increase in the number of patients with stage III CRC who received adjuvant chemotherapy from 37% in the first decade to 51% in the latter decade.

In conclusion, right-sided tumour location was associated with host characteristics, features of the tumour microenvironment and the SIR, but not survival in patients undergoing potentially curative surgery for stage I--III CRC. Future studies investigating the role of tumour location in a prognostic or predictive capacity should be aware of the potential confounding role that inflammatory responses may have in these patients.
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###### Associations between right/left/rectal tumours and clinicopathological characteristic, systemic inflammation and the tumour microenvironment in patients undergoing elective surgery for stage I--III colorectal cancer

  **All;** ***n*****=972 (%)**               **All;** ***n*****=972 (%)**   **Right;** ***n*****=389 (%)**   **Left;** ***n*****=285 (%)**   **Rectal;** ***n*****=298 (%)**   ***P***
  ----------------------------------------- ------------------------------ -------------------------------- ------------------------------- --------------------------------- ---------
  **Host characteristics**                                                                                                                                                    
  Age (*n*=972)                                                                                                                                                                    
   \<65                                                314 (32)                        101 (26)                        101 (36)                         112 (38)                0.001
   65--74                                              343 (35)                        135 (35)                         98 (34)                         110 (37)                   
   \>75                                                315 (33)                        153 (39)                         86 (30)                          76 (25)                   
  Sex (*n*=972)                                                                                                                                                                    
   Female                                              438 (45)                        188 (48)                        132 (46)                         118 (40)                0.065
   Male                                                534 (55)                        201 (52)                        153 (54)                         180 (60)                   
  ASA status (*n*=907)                                                                                                                                                             
   1                                                   162 (18)                        52 (14)                          48 (19)                          90 (23)                0.088
   2                                                   406 (45)                        164 (44)                        113 (44)                         179 (46)                   
   3                                                   302 (33)                        138 (37)                         82 (32)                         115 (29)                   
   4                                                    37 (4)                          17 (5)                          12 (5)                            9 (2)                    
  **Tumour characteristics**                                                                                                                                                  
  T stage (*n*=969)                                                                                                                                                                
   1--2                                                207 (21)                        57 (15)                          65 (23)                          85 (29)               \<0.001
   3                                                   531 (55)                        216 (56)                        150 (53)                         165 (55)                   
   4                                                   231 (24)                        115 (29)                         69 (24)                          47 (16)                   
  N stage (*n*=275)                                                                                                                                                                
   0                                                   617 (64)                        248 (64)                        192 (67)                         177 (59)                0.320
   1                                                   259 (26)                        101 (26)                         71 (25)                          87 (29)                   
   2                                                   95 (10)                         39 (10)                          22 (8)                           34 (11)                   
  TNM stage (*n*=971)                                                                                                                                                              
   I                                                   178 (18)                        53 (14)                          58 (20)                          67 (23)                0.002
   II                                                  437 (45)                        194 (50)                        134 (47)                         109 (37)                   
   III                                                 356 (37)                        142 (36)                         93 (33)                         121 (40)                   
  Tumour differentiation (*n*=961)                                                                                                                                                 
   Mod/well                                            870 (90)                        323 (84)                        272 (96)                         275 (93)               \<0.001
   Poor                                                91 (10)                         62 (16)                           9 (4)                           20 (7)                    
  Venous invasion (*n*=971)                                                                                                                                                        
   No                                                  486 (50)                        180 (46)                        162 (57)                         144 (48)                0.021
   Yes                                                 485 (50)                        208 (54)                        123 (43)                         154 (52)                   
  Margin involvement (*n*=971)                                                                                                                                                     
   No                                                  919 (95)                        370 (95)                        271 (95)                         278 (93)                0.466
   Yes                                                  52 (5)                          18 (5)                          14 (5)                           20 (7)                    
  Necrosiss                                                                                                                                                                        
   Absent                                              191 (58)                        70 (58)                          57 (54)                          64 (63)                0.422
   Present                                             138 (42)                        51 (42)                          49 (46)                          38 (37)                   
  MMR (*n*=228)                                                                                                                                                                    
   Competent                                           193 (85)                        65 (75)                          57 (89)                          71 (92)                0.005
   Deficient                                           35 (15)                         22 (25)                          7 (11)                            6 (8)                    
  BRAF (*n*=221)                                                                                                                                                                   
   Wild type                                           169 (77)                        61 (73)                          50 (78)                          58 (80)                0.566
   V600E mutation                                      52 (23)                         23 (27)                          14 (22)                          15 (20)                   
  **Tumour microenvironment**                                                                                                                                                 
  Klintrup--Mäkinen grade (*n*=353)                                                                                                                                                
   Weak                                                233 (66)                        88 (70)                          73 (64)                          72 (64)                0.431
   Strong                                              120 (34)                        37 (30)                          42 (36)                          41 (36)                   
  Tumour stroma percentage (*n*=302)                                                                                                                                               
   Low                                                 228 (76)                        92 (78)                          71 (76)                          65 (71)                0.543
   High                                                74 (24)                         26 (22)                          22 (24)                          26 (29)                   
  CD3+ margin density (*n*=260)                                                                                                                                                    
   Low                                                 148 (57)                        54 (59)                          36 (48)                          58 (62)                0.160
   High                                                112 (43)                        38 (41)                          39 (52)                          35 (38)                   
  CD3+ cancer cell nest density (*n*=270)                                                                                                                                          
   Low                                                 173 (64)                        55 (57)                          47 (62)                          83 (74)                0.048
   High                                                97 (36)                         42 (43)                          29 (38)                          29 (26)                   
  CD8+ margin density (*n*=257)                                                                                                                                                    
   Low                                                 150 (58)                        53 (60)                          38 (50)                          59 (63)                0.194
   High                                                107 (42)                        35 (40)                          38 (50)                          34 (37)                   
  CD8+ cancer cell nest density (*n*=266)                                                                                                                                          
   Low                                                 185 (70)                        63 (68)                          52 (68)                          70 (73)                0.666
   High                                                81 (30)                         30 (32)                          25 (32)                          26 (27)                   
  **Systemic inflammation**                                                                                                                                                   
  mGPS (*n*=926)                                                                                                                                                                   
   0                                                   658 (71)                        235 (64)                        201 (75)                         222 (77)               \<0.001
   1                                                   163 (18)                        69 (19)                          44 (16)                          50 (17)                   
   2                                                   105 (11)                        62 (17)                          25 (9)                           18 (6)                    
  Neutrophil:lymphocyte ratio (*n*=814)                                                                                                                                            
   Low                                                 708 (87)                        283 (85)                        201 (90)                         224 (88)                0.214
   High                                                106 (13)                        51 (15)                          23 (10)                          32 (12)                   
  Neutrophil:platelet score (*n*=817)                                                                                                                                              
   0                                                   667 (82)                        239 (72)                        204 (87)                         224 (90)               \<0.001
   1                                                   116 (14)                        71 (21)                          23 (10)                          22 (8)                    
   2                                                    34 (4)                          23 (7)                           7 (3)                            4 (2)                    
  Lymphocyte:monocyte ratio (*n*=972)                                                                                                                                              
   Low                                                 155 (16)                        80 (21)                          39 (14)                          36 (12)                0.005
   High                                                817 (84)                        309 (79)                        246 (86)                         262 (88)                   
  Adjuvant therapy (*n*=970)                                                                                                                                                       
   1997--2006                                                                                                                                                                      
   No                                                  286 (78)                        107 (84)                         92 (78)                          87 (69)                0.632
   Yes                                                 86 (22)                         21 (16)                          26 (22)                          39 (31)                   
   2007--2016                                                                                                                                                                      
   No                                                  409 (68)                        184 (61)                        125 (75)                         100 (58)                   
   Yes                                                 189 (32)                        75 (29)                          42 (25)                          72 (42)                   
  5-year CSS % (s.e.)                                                                   79 (3)                          83 (3)                           76 (3)                 0.377
  5-year OS % (s.e.)                                                                    66 (3)                          71 (3)                           67 (3)                 0.205

Abbreviations: ASA=American Society of Anesthesiology physical status classification; CSS=cancer-specific survival; mGPS=modified Glasgow Prognostic Score; MMR=mismatch repair; OS=overall survival; TNM=tumour, node, metastasis.

###### Associations between right/left/rectal tumours and clinicopathological characteristic, systemic inflammation and the tumour microenvironment in patients who have undergone adjuvant chemotherapy following elective surgery for stage I-III colorectal cancer

                                            **All;** ***n*****=275 (%)**   **Right;** ***n*****=96 (%)**   **Left;** ***n*****=68 (%)**   **Rectal;** ***n*****=111 (%)**   ***P***
  ---------------------------------------- ------------------------------ ------------------------------- ------------------------------ --------------------------------- ---------
  **Host characteristics**                                                                                                                                                 
  Age (*n*=275)                                                                                                                                                                 
   \<65                                               144 (52)                        44 (46)                        39 (57)                          61 (55)                0.583
   65--74                                             101 (37)                        39 (41)                        23 (34)                          39 (35)                   
   \>75                                               30 (11)                         13 (13)                         6 (9)                           11 (10)                   
  Sex (*n*=275)                                                                                                                                                                 
   Female                                             121 (44)                        43 (45)                        36 (53)                          42 (38)                0.139
   Male                                               154 (56)                        53 (55)                        32 (47)                          69 (62)                   
  ASA status (*n*=256)                                                                                                                                                          
   1                                                  70 (27)                         23 (25)                        20 (32)                          27 (27)                0.711
   2                                                  119 (47)                        46 (50)                        29 (46)                          44 (44)                   
   3                                                  62 (24)                         20 (22)                        13 (20)                          29 (28)                   
   4                                                   5 (2)                           3 (3)                          1 (2)                            1 (1)                    
  **Tumour characteristics**                                                                                                                                               
  T stage (*n*=275)                                                                                                                                                             
   1--2                                                22 (9)                          1 (1)                          8 (12)                          13 (12)               \<0.001
   3                                                  163 (59)                        50 (52)                        37 (54)                          76 (68)                   
   4                                                  90 (32)                         45 (47)                        23 (34)                          22 (20)                   
  N stage (*n*=275)                                                                                                                                                             
   0                                                  85 (31)                         31 (32)                        23 (34)                          37 (28)                0.398
   1                                                  134 (49)                        46 (48)                         3 (53)                          52 (47)                   
   2                                                  56 (20)                         19 (20)                         9 (13)                          28 (25)                   
  TNM stage (*n*=275)                                                                                                                                                           
   I                                                   3 (1)                           0 (0)                          0 (0)                            3 (3)                 0.141
   II                                                 81 (30)                         30 (31)                        23 (34)                          28 (25)                   
   III                                                191 (70)                        66 (69)                        45 (66)                          80 (72)                   
  Tumour differentiation (*n*=274)                                                                                                                                              
   Mod/well                                           244 (89)                        81 (84)                        65 (96)                          98 (89)                0.058
   Poor                                               30 (11)                         15 (16)                         3 (4)                           12 (11)                   
  Venous invasion (*n*=275)                                                                                                                                                     
   No                                                 92 (34)                         23 (24)                        24 (35)                          45 (41)                0.036
   Yes                                                183 (66)                        73 (76)                        44 (65)                          66 (59)                   
  Margin involvement (*n*=275)                                                                                                                                                  
   No                                                 246 (90)                        88 (92)                        62 (91)                          96 (87)                0.423
   Yes                                                29 (10)                          8 (8)                          6 (9)                           15 (13)                   
  Necrosis (*n*=87)                                                                                                                                                             
   Absent                                             47 (54)                         11 (48)                        16 (57)                          20 (56)                0.779
   Present                                            40 (46)                         12 (52)                        12 (43)                          16 (44)                   
  MMR (*n*=66)                                                                                                                                                                  
   Competent                                          58 (88)                         19 (86)                        18 (95)                          21 (84)                0.509
   Deficient                                           8 (12)                         3 (14)                          1 (5)                           4 (16)                    
  BRAF (*n*=62)                                                                                                                                                                 
   Wild type                                          46 (74)                         15 (75)                        13 (65)                          18 (82)                0.460
   V600E mutation                                     16 (26)                         5 (25)                          7 (35)                          4 (18)                    
  **Tumour microenvironment**                                                                                                                                              
  Klintrup--Mäkinen grade (*n*=102)                                                                                                                                             
   Weak                                               30 (29)                         10 (40)                        10 (31)                          10 (22)                0.285
   Strong                                             72 (71)                         15 (60)                        22 (69)                          35 (78)                   
  Tumour stroma percentage (*n*=79)                                                                                                                                             
   Low                                                54 (68)                         15 (68)                        18 (72)                          21 (66)                0.875
   High                                               25 (32)                         7 (32)                          7 (28)                          11 (34)                   
  CD3+ margin density (*n*=71)                                                                                                                                                  
   Low                                                42 (59)                         9 (47)                         10 (46)                          23 (77)                0.033
   High                                               29 (41)                         10 (53)                        12 (54)                          7 (23)                    
  CD3+ cancer cell nest density (*n*=73)                                                                                                                                        
   Low                                                58 (80)                         12 (60)                        17 (77)                          29 (94)                0.012
   High                                               15 (20)                         8 (40)                          5 (23)                           2 (6)                    
  CD8+ margin density (*n*=71)                                                                                                                                                  
   Low                                                37 (52)                         11 (58)                         9 (43)                          17 (55)                0.586
   High                                               34 (48)                         8 (42)                         12 (57)                          14 (45)                   
  CD8+ cancer cell nest density (*n*=73)                                                                                                                                        
   Low                                                55 (75)                         16 (76)                        14 (67)                          25 (81)                0.522
   High                                               18 (25)                         5 (24)                          7 (33)                          6 (19)                    
  **Systemic inflammation**                                                                                                                                                
   mGPS (*n*=257)                                                                                                                                                               
   0                                                  190 (74)                        56 (68)                        49 (75)                          85 (78)                0.597
   1                                                  47 (18)                         19 (23)                        11 (17)                          17 (16)                   
   2                                                   20 (8)                          8 (9)                          5 (8)                            7 (6)                    
  Neutrophil:lymphocyte ratio (*n*=249)                                                                                                                                         
   Low                                                217 (87)                        80 (88)                        53 (93)                          84 (83)                0.183
   High                                               32 (13)                         11 (12)                         4 (7)                           17 (17)                   
  Neutrophil:platelet score (*n*=239)                                                                                                                                           
   0                                                  189 (79)                        63 (70)                        46 (85)                          80 (84)                0.066
   1                                                  40 (17)                         23 (26)                         5 (9)                           12 (13)                   
   2                                                   10 (4)                          4 (4)                          3 (6)                            3 (3)                    
  Lymphocyte:monocyte ratio (*n*=275)                                                                                                                                           
   Low                                                39 (14)                         17 (18)                         5 (7)                           17 (15)                0.128
   High                                               236 (86)                        79 (82)                        63 (93)                          94 (85)                   
  5-year CSS % (s.e.)                                                                 80 (5)                          85 (5)                           7 (5)                 0.302
  5-year OS % (s.e.)                                                                  74 (5)                          85 (5)                          66 (5)                 0.076

Abbreviations: ASA=American Society of Anesthesiology physical status classification; CSS=cancer-specific survival; mGPS=modified Glasgow Prognostic Score; MMR=mismatch repair; OS=overall survival.
